Business
Nuwellis Announces Purchase Agreement with a 50 Hospital Network for Aquadex Ultrafiltration Therapy
MINNEAPOLIS, May 09, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with
About this update from Nuwellis, Inc.
[{"type":"text","content":"MINNEAPOLIS, May 09, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced a new purchase agreement with one of the top 25 largest integrated delivery networks (IDN) in the U.S. Nuwellis has a successful history of collaborating with individual member hospitals within the IDN on Aquadex utilization. This new network-wide agreement signifies a broader commitment to providing advanced ultrafiltration technology to improve patient care across the entire 50 hospital system. “We are thrilled to be working with this leading hospital network to expand access to Aquadex therapy for a wider range of heart failure, critical care, and pediatric patients,” said Nestor Jaramillo, Jr., President and Chief Executive Officer at Nuwellis. “Aquadex offers a safe and effective ultrafiltration option for patients with fluid overload who are unresponsive to diuretics, and this agreement demonstrates the dedication of this IDN to provide innovative treatment options for its patients and economic benefits to the hospitals in the system.” This agreement comes on the heels of exciting new data presented at the recent Technology and Heart Failure Therapeutics (THT) conference in early March. During a late-breaking clinical trials session, the data showed a clinically and statistically significant reduction in both 30-day hospitalizations and heart failure events for patients treated with Aquadex. This clinical data milestone aligns with Nuwellis' ongoing commitment to build a robust body of clinical and economic evidence supporting the use of Aquadex for managing fluid overload in patients unresponsive to diuretics.1 About the Aquadex SmartFlow® System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physi...